nach oben

Annals of Hematology

Erschienen in:

19.08.2016 | Review Article

Primary myelofibrosis and its targeted therapy

verfasst von: Lindsey Shantzer, Kristin Berger, Jeffrey J. Pu

Erschienen in: Annals of Hematology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Primary myelofibrosis is a unique entity among BCR-ABL-negative myeloproliferative diseases, manifesting as bone marrow fibrosis and pancytopenia. Considerable evidence indicates that genetic and epigenetic abnormalities can result in defective clonal hematopoietic stem cell proliferation in addition to bone marrow microenvironment alteration. The “bad seeds in bad soil” theory illustrates the orchestrating efforts of hematopoietic stem cells, stromal cells, and their surrounding signaling molecules in myelofibrosis progression and malignancy transformation, though the exact mechanism of myelofibrosis is still not clear. This study reviews current concepts and questions regarding the pathogenesis of primary myelofibrosis and discusses the emerging targeted therapy aimed at restoring normal bone marrow environment and halting bone marrow fibrotic deterioration.

Tefferi A (2013) Primary myelofibrosis: 2013 update on diagnosis, risk–stratification, and management. Am J Hematol 88(2):141–150CrossRefPubMed

Mesa RA, Li CY, Ketterling RP et al (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105(3):973–977CrossRefPubMed

Arber DA, Attilio O, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRefPubMed

Thiele J, Kvasnicka HM, Müllauer L et al (2011) Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 117(21):5710–5718CrossRefPubMed

Kvasnicka HM, Thiele J (2010) Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 85(1):62–69PubMed

Barbui T, Thiele J, Passamonti F et al (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29(23):3179–3184CrossRefPubMed

Barosi G, Mesa RA, Thiele J et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22(2):437–438CrossRefPubMed

Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901CrossRefPubMed

Passamonti F, Cervantes F, Vannucchi AM et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703–1708CrossRefPubMed

10.

Gangat N, Caramazza D, Vaidya R et al (2011) DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29(4):392–397CrossRefPubMed

11.

Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779–1790CrossRefPubMed

12.

Scott LM, Tong W, Levine RL et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356.5:459–468CrossRef

13.

Pikman Y, Lee BH, Mercher T et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3.7:e270CrossRef

14.

Oh ST, Simonds EF, Jones C et al (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116(6):988–992CrossRefPubMedPubMedCentral

15.

Vainchenker W, Constantinescu SN, Plo I (2016) Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000Res 5:700CrossRef

16.

Chachoua I, Pecquet C, El-Khoury M et al (2016) Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 127(10):1325–1335CrossRefPubMed

17.

Castro-Malaspina H, Jhanwar SC (1984) Properties of myelofibrosis-derived fibroblasts. Prog Clin Biol Res 154:307–322PubMed

18.

Bonner JC (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth F R 15(4):255–273CrossRef

19.

Barosi G (2014) Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. Best Pract Res Clin Haematol 27(2):129–140CrossRefPubMed

20.

Bock O, Höftmann J, Theophile K et al (2008) Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. Am J Pathol 172(4):951–960CrossRefPubMedPubMedCentral

21.

Steurer M, Zoller H, Augustin F et al (2007) Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Hum Pathol 38(7):1057–1064CrossRefPubMed

22.

Bock O, Loch G, Schade U et al (2005) Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. Br J Haematol 130(1):76–82CrossRefPubMed

23.

Martinaud C, Desterke C, Konopacki J et al (2015) Osteogenic potential of mesenchymal stromal cells contributes to primary myelofibrosis. Cancer Res 75(22):4753–4765CrossRefPubMed

24.

Wang JC, Sindhu H, Chen C et al (2015) Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα. PLoS One 10(3):e0116723CrossRefPubMedPubMedCentral

25.

Harrison JS, Corcoran KE, Joshi D et al (2006) Peripheral monocytes and CD4+ cells are potential sources for increased circulating levels of TGF-beta and substance P in autoimmune myelofibrosis. Am J Hematol 81(1):51–58CrossRefPubMed

26.

Desterke C, Martinaud C, Ruzehaji N, Le Bousse-Kerdilès MC (2015) Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis. Mediators Inflamm 2015:415024CrossRefPubMedPubMedCentral

27.

Schepers P, Pietras EM, Reynaud D et al (2013) Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13(3):285–299CrossRefPubMedPubMedCentral

28.

Verstovsek S, Kantarjian H, Mesa RA et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117–1127CrossRefPubMedPubMedCentral

29.

Hoermann G, Greiner G, Valent P (2015) Cytokine regulation of microenvironmental cells in myeloproliferative neoplasms. Mediators Inflamm 2015:869242CrossRefPubMedPubMedCentral

30.

Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807CrossRefPubMedPubMedCentral

31.

Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787–798CrossRefPubMed

32.

Verstovsek S, Mesa RA, Gotlib J et al (2015) Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100(4):479–488CrossRefPubMedPubMedCentral

33.

Vannucchi AM, Kantarjian HM, Kiladjian JJ et al (2015) A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 100(9):1139–1145CrossRefPubMedPubMedCentral

34.

Kvasnicka HM, Thiele J, Bueso-Ramos CE et al (2014) Ruxolitinib-induced modulation of bone marrow microenvironment in patients with myelofibrosis is associated with inflammatory cytokine levels. Blood 124(21):3182–3182

35.

Tefferi A, Litzow MR, Pardanani A (2011) Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365(15):1455–1457CrossRefPubMed

36.

Geyer HL, Mesa RA (2015) Emerging drugs for the treatment of myelofibrosis. Expert Opin Emerg Drugs 20(4):663–678CrossRefPubMed

37.

Grunwald MR, Spivak JL (2014) Ruxolitinib enhances platelet production in patients with thrombocytopenic myelofibrosis. J Clin Oncol 34(5):e38–e40CrossRefPubMed

38.

Komrokji RS, Seymour JF, Roberts AW et al (2015) Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2 (V617F) inhibitor, in patients with myelofibrosis. Blood 125(17):2649–2655CrossRefPubMedPubMedCentral

39.

Teglund S, Toftgård R (2010) Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 1805(2):181–208PubMed

40.

Tibes R, Mesa RA (2014) Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. J Hematol Oncol 7:18CrossRefPubMedPubMedCentral

41.

Keller MD, Rampal RK, Shank K et al (2013) Improved efficacy of combination of JAK2 and hedgehog inhibitors in myelofibrosis. Blood 122:666CrossRef

42.

Tefferi A, Lasho TL, Begna KH et al (2015) A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 373(10):908–919CrossRefPubMed

43.

Wen QJ, Yang Q, Goldenson B et al (2015) Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med 21(12):1473–1480CrossRefPubMedPubMedCentral

44.

Wang JC, Chen C, Dumlao T et al (2008) Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma 49(12):2321–2327CrossRefPubMed

45.

Ugo V, Marzac C, Teyssandier I et al (2004) Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 32(2):179–187CrossRefPubMed

46.

Grimwade LF, Happerfield L, Tristram C et al (2009) Phospho–STAT5 and phospho–Akt expression in chronic myeloproliferative neoplasms. Br J Haematol 147(4):495–506CrossRefPubMed

47.

Guglielmelli P, Barosi G, Rambaldi A et al (2011) Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 118(8):2069–2076CrossRefPubMedPubMedCentral

Titel: Primary myelofibrosis and its targeted therapy
verfasst von: Lindsey Shantzer
Kristin Berger
Jeffrey J. Pu
Publikationsdatum: 19.08.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 4/2017
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-016-2785-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Primary myelofibrosis and its targeted therapy

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Blastic plasmacytoid dendritic cell neoplasm with transient response to pralatrexate

Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia

Rare myopathy associated to MGUS, causing heart failure and responding to chemotherapy

Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements

Histoplasma capsulatum in a peripheral blood smear in a non-HIV patient

Haploidentical hematopoietic bone marrow transplantation followed by living kidney transplantation from the same donor in a sickle cell disease patient with end-stage renal failure

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Update Innere Medizin